Search

Memorial Sloan Kettering’s new research complex contains more than 100 laboratories, nearly doubling the space we dedicate to research to better understand and treat cancer.

… Wednesday, October 17, 2012 Summary Memorial Sloan Kettering’s new research complex contains more than 100 laboratories, nearly doubling the space we dedicate to research to better understand and treat cancer. Construction on the Mortimer B. Zuckerman Research Center – named in recognition of the $100

The US Food and Drug Administration (FDA) has approved the drug naxitamab (Danyelza) for the treatment of patients with high-risk neuroblastoma. The drug, also known as humanized 3F8, was developed by researchers at MSK Kids, the pediatric cancer program at Memorial Sloan Kettering.

… Tuesday, January 5, 2021 The US Food and Drug Administration (FDA) has approved the drug naxitamab (Danyelza) for the treatment of patients with high-risk neuroblastoma.  The drug , also known as humanized 3F8, was developed by researchers at MSK Kids, the pediatric cancer program at Memorial Sloan Kettering

美国食品药品监督管理局 (FDA) 已批准将 naxitamab (Danyelza) 用于高危神经母细胞瘤患者的治疗。 该药物也称为人源化 3F8，由纪念斯隆凯特琳儿科癌症项目 MSK 斯隆儿科项目的研究人员开发。

… Tuesday, January 5, 2021 美国食品药品监督管理局 (FDA) 已批准将 naxitamab (Danyelza) 用于高危神经母细胞瘤患者的治疗。 该药物 也被称为人源化 3F8，由纪念斯隆凯特琳儿科癌症项目 MSK 斯隆儿科项目的研究人员开发。 Naxitamab 的临床试验由儿科肿瘤医生 Brian Kushner 和 MSK 斯隆儿科项目的神经母细胞瘤团队主导开展。 如今美国和全球的患者将更容易获得这种治疗。 神经母细胞瘤 是一种罕见的神经组织癌症，通常源于腹部。 其主要影响幼儿群体。 尽管过去这种疾病在几乎所有的高危病例中都是致命的，但在过去的二十年中，其前景得到了相当大的改善

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) are conducting a range of clinical trials of promising new treatments for patients with non-muscle invasive bladder cancer (NMIBC).

… Monday, April 29, 2024 MSK Clinical Trials for Patients with BCG-Naïve, BCG-Exposed, and BCG-Unresponsive Bladder Cancer Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) are conducting a range of clinical trials of promising new treatments for patients with non-muscle invasive bladder

Memorial Sloan Kettering is joining with two other academic institutions in a pioneering collaboration to speed early-stage drug discoveries into therapies for patients.

… Friday, October 25, 2013 Summary Memorial Sloan Kettering is joining with two other academic institutions in a pioneering collaboration to speed early-stage drug discoveries into therapies for patients. Despite tremendous advances in medical research in recent decades, the number of new treatments that

Researchers at Memorial Sloan Kettering have shown the usefulness of a scale called the Bone Scan Index (BSI) for determining whether some prostate cancer patients are responding to therapy.

… Friday, January 13, 2012 Summary Researchers at Memorial Sloan Kettering have shown the usefulness of a scale called the Bone Scan Index (BSI) for determining whether some prostate cancer patients are responding to therapy. Researchers at Memorial Sloan Kettering have shown the usefulness of a scale

… Tuesday, February 8, 2022 2022 Black History Month Employee Profiles Carl Sanon, Assistant Manager, Outpatient Operations, Ralph Lauren Center When Carl was a junior at Binghamton University, he received an opportunity to work at MSK as a summer support intern. Initially, he saw it as a chance to make

While numerous summer student internships were cancelled this year due to the pandemic, MSK quickly modified many of our summer student programs to enroll more than 300 interns from around the world – both virtually and in-person.

… Monday, August 24, 2020 While numerous summer internships in the United States and abroad were cancelled this year due to the pandemic, Memorial Sloan Kettering (MSK) has kept many internship programs running – both virtually and in-person. This summer, more than 300 interns from around the world were

A sensitive assay for detecting tumor DNA in the blood performed well in patients and may herald the development of a blood test for cancer screening.

… Saturday, June 3, 2017 Summary Sophisticated laboratory assays for detecting and sequencing small amounts of DNA are revolutionizing biology and medicine. At ASCO, the world’s largest cancer meeting, scientists from MSK are reporting that a new and highly sensitive genomic sequencing assay can be used

This CAR T Update Part 2 summarizes the unique challenges with using CARS to defeat solid tumors, and how learning from preclinical and clinical research in hematologic malignancies is informing new strategies and research efforts.

… Thursday, June 11, 2020 New and emerging information about chimeric antigen receptor (CAR) T cell therapy in the setting of hematologic malignancies is informing strategies for overcoming obstacles in solid tumors. In our paper, published recently in the journal Expert Review of Hematology , we discuss